NCT03050619View on ClinicalTrials.gov

Characteristics of Empagliflozin Initiators

CompletedOBSERVATIONAL
Enrollment

31,908

Participants

Timeline

Start Date

September 10, 2016

Primary Completion Date

October 14, 2016

Study Completion Date

October 14, 2016

Conditions
Type 2 Diabetes
Interventions
DRUG

Empagliflozin

DRUG

Other SGLT2 inhibitors

DRUG

Other non-insulin GLDs

metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists

Trial Locations (1)

Unknown

Boehringer Ingelheim Investigational Site, Ingelheim

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY